A321 HDL-C and LDL-C of 1.51 (P 0.02) and 1.02 (P 0.02). Alternatively, a 1% increase in HDL-C equates to a 1.5% change in cardiovascular events while a 1% reduction in LDL-C equates to a 1% reduction in those events. HDL-C is statistically significantly inversely related to mortality. Higher HDL-C is associated with a decrease in the likelihood of death ( 1.73; P 0.04) while repeated measures that are higher further decrease that probability ( 0.01: P 0.02). Lower LDL-C decreases the probability of death. CONCLUSIONS: The relationship between HDL-C and allcause mortality was quantified, replicated and validated and shown to be of greater prognostic value than LDL-C. OBJECTIVES: Approximately 230,000 percutaneous coronary interventions (PCIs) were performed in the Germany in 2005. PCI complications often increase resource utilization. New antithrombotic therapies have the potential to improve outcomes and New antithrombotic therapies have the potential to improve outcomes and decrease costs. The ACUITY and HORIZONS-AMI studies demonstrated improved clinical event rates (mortality and bleeding) using bivalirudin compared to a heparinplus-GPI regimen. This analysis evaluated the economic impact of this improvement in the German hospital setting. METHODS: A budget-impact model was developed to evaluate the impact of bivalirudin in unstable angina (UA)/non-ST-elevated myocardial infarction (NSTEMI) patients undergoing PCI in a German hospital. Clinical data for the model were derived from the ACUITY trial and included 30-day event rates for major complications (major and minor bleeding as defined by trial protocol, Q-wave myocardial infarction, repeat PCI and coronary artery bypass graft [CABG]). Economic data were derived from the medical literature, including clinical outcomes as well as ward costs (both regular and ICU/CCU) and pharmaceutical costs. Additional analysis using resource use data from the ADONIS registry was performed. A subgroup of high risk patients (per ESC definition) was also examined in the model. RESULTS: For UA/NSTEMI patients, overall average per procedure cost was a5347 with heparin plus GPI and a4822 with bivalirudin. In 100 PCI patients, bivalirudin use would result in 3 fewer major bleeding events (3.1%) and 11 fewer minor bleeding events (10.7%). Total hospital costs comparing 100% heparin-based strategy to 100% bivalirudin-based strategy were a341,473 and a289,025, respectively, resulting in a cost-savings with bivalirudin of a52,448 (15%). For high risk UA/NSTEMI patients the cost-savings over 100 procedures are a56,233 (16%). CONCLUSIONS: A bivalirudin-based strategy for anticoagulant use in UA/NSTEMI patients undergoing PCI is associated with favorable clinical and economic outcomes when compared with heparin plus GPI in a German hospital setting.
PCV49 FINANCIAL IMPACT OF A NOVEL PREECLAMPSIA DIAGNOSTIC TEST VS. STANDARD CARE: A DECISION-ANALYTIC MODELING ANALYSIS FROM A GERMAN HEALTH CARE PAYER PERSPECTIVE
Hadker N 1 , Garg S 1 , Costanzo C 1 , Miller JD 1 , van der Helm W 2 , Foster T 1 , Creeden J 2 1 Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2 Roche Diagnostics, Ltd, Rotkreuz, Switzerland OBJECTIVES: Preeclampsia, a leading cause of maternal and perinatal morbidity and mortality, is only detected after the onset of clinical symptoms. Earlier diagnosis may be possible with a new serum test using soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) biomarkers. Clinical and economic benefits may result from appropriate detection and management of subclinical cases, and from averting costs associated with incorrect diagnoses. We evaluated the financial impact of the novel test versus standard care from a German health care payer perspective.
METHODS:
We developed a decision-analytic model of the clinical and economic impact resulting from improved sensitivity and specificity of the new test over current diagnostic practice. Acute management and follow-up costs were associated with true positive, true negative, false positive, and false negative diagnoses. The base-case analysis assumed that, of all pregnant women, 10% present with risk factors while 90% do not. The CHF 52 (a-equivalent) test was assumed to be administered after 20 weeks of gestation. True positive and false negative patients were assumed to enter one of four health states: mild preeclampsia; severe preeclampsia; eclampsia; or death. Data pertaining to treatment practices, health care resource utilization, incidence, costs, and funding for detection and management of preeclampsia in Germany were obtained through interviews with clinicians, laboratory managers, and health care payers in Germany. Additional data were obtained from published literature and public databases. RESULTS: Model results suggest that when used for screening, the novel test would reduce false negative diagnoses of preeclampsia by 67% and false positives by 71%. Costs per patient are estimated to be a941 with the novel test and a1578 with standard practice, saving an estimated a637 per patient given the novel test. CONCLUSIONS: This test has the potential to improve detection and management of preeclampsia translating into substantial cost savings for German health care payers.
PCV50 BUDGET IMPACT OF BIVALIRUDIN IN STEMI PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION (PPCI) IN UK HOSPITALS
Olchanski N 1 , Slawsky K 1 , Cyr PL 1 , Schwenkglenks M 2 , Kinnaird T 3 1 Boston Healthcare Associates, Inc., Boston, MA, USA, 2 University of Basel, Basel, Switzerland, 3 University Hospital of Wales, Cardiff, UK OBJECTIVES: Approximately 5900 PPCIs were performed in the UK in 2007. This number is expected to double in the next 5 years post the 2008 NIAP report. New antithrombotic therapies have the potential to improve clinical outcomes and decrease costs. The HORIZONS-AMI study of bivalirudin demonstrated reduced clinical event rates (mortality and bleeding) compared to a heparin and GPI (HEP GPI) regimen. The potential economic value of implementing bivalirudin in the PPCI setting is evaluated in this analysis from the UK hospital perspective. METHODS: A budget impact model was developed to compare treatment of STEMI patients undergoing PPCI with either bivalirudin or HEP GPI. Clinical data for the model was derived from the HORIZONS trial, and included 30-day event rates for major complications (major and minor bleeding as defined by trial protocol, Q-wave myocardial infarction [MI], and repeat PCI and coronary artery bypass graft [CABG] procedures). UK cost and clinical practice data were derived from published sources. RESULTS: Overall average procedure cost per bivalirudin-treated patient (incorporating 7.2% provisional GPI use as per HORIZONS) was £4284, compared to £5015 per HEP GPI-treated patient. In extrapolating these benefits to a typical NHS hospital of 200 PPCI patients per year, 7 major bleeding events (3.4%), 13 minor bleeding events (6.6%), and 2 deaths (1%) in patients would be averted if treated with bivalirudin. The total hospital budget impact of treating 200 PPCI patients using a HEP GPI based strategy is £1,002,913. Introducing a bivalirudin-based strategy could save £146,129 (15%) per year. CON-CLUSIONS: Using a bivalirudin-based strategy in STEMI patients undergoing PPCI is associated with favorable clinical and economic outcomes when compared with HEP GP in a UK hospital setting.
PCV51 THE POTENTIAL ECONOMIC IMPACT OF RECONFIGURING TIA CARE IN ITALY
Jackson D 1 , Moshinsky J 2 , Begg A 2 1 GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK, 2 Medaxial Group, London, UK OBJECTIVES: Due to a lack of awareness of Transient Ischaemic Attack (TIA) symptoms, many patients may not immediately seek medical help, creating a delay in access to treatment. The UK EXPRESS study by Rothwell et al. (Lancet 2007; 370:1432-42 ) demonstrated that greater focus on effectively managing TIA could have a significant impact on subsequent stroke rates. With nearly 200,000 strokes occurring in Italy each year, we wanted to examine how a shift in care pathways towards that outlined in phase 2 of the EXPRESS study could affect rates of stroke, and explore the financial implications of such a shift in care pathway. METHODS: We developed an economic model to estimate the costs and savings associated with establishing a rapid assessment and treatment clinic for patients with suspected TIA in Italy, in line with phase 2 of the EXPRESS study. We used a population of 1,000,000 people with an assumed annual incidence of TIA of 0.058%. Current management was based on ESO guidelines and common clinical practice. We included direct costs associated with care (medications, diagnostics and staff-where data were unavailable, UK converted costs were used), and modelled the impact of changing management over three years. RESULTS: For a population of 1,000,000, changing the pathway of care to ensure rapid assessment and treatment for TIA patients would result in 180 future stroke events being avoided over three years. As a result, additional costs associated with changing the TIA pathway of care were offset by savings generated through avoiding acute stroke management costs. CONCLUSIONS: Our model suggests that implementing a revised TIA care pathway in Italy would be cost saving. For a local population of 1,000,000, savings associated with the avoidance of acute stroke management would offset the costs of establishing rapid assessment and treatment clinics for patients experiencing TIA.
PCV52 RECONFIGURING TIA CARE PATHWAYS IN HUNGARY: AVOIDING RECURRENT STROKE
Jackson D 1 , Moshinsky J 2 , Begg A 2 1 GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK, 2 Medaxial Group, London, UK OBJECTIVES: Due to lack of awareness of Transient Ischaemic Attack (TIA) symptoms, many patients may not immediately seek medical help, creating a delay in access to treatment. The UK EXPRESS study by Rothwell et al. (Lancet 2007; 370:1432-42) demonstrated that greater focus on rapid assessment and management of TIA could significantly reduce subsequent stroke rates. With over 42,000 hospitalisations due to strokes in Hungary each year, we wanted to examine how a shift in care pathways towards that outlined in the EXPRESS study could affect stroke rates, and explore the financial implications of such a shift in care pathway. METHODS: We developed an economic model to estimate the costs and savings associated with establishing a rapid assessment and treatment clinic for patients with suspected TIA in Hungary, in line with phase 2 of the EXPRESS study. We used a population of 1,000,000 with an assumed annual TIA incidence of 0.042%. Current management was based on ESO guidelines and common clinical practice. We included direct costs associated with secondary care (medications, diagnostics and staff-where data were unavailable, converted UK costs were used), and modelled the impact of changing management over a three-year time horizon. RESULTS: For a population of 1,000,000, changing
